Riter’s appointment signals a strategic push for DDL to deepen its technical bench. She arrives from Kindeva Drug Delivery, where she served as Vice President of Analytical and Development Services, overseeing global organizations and scaling testing infrastructure. Her tenure prior to Kindeva included a substantial 30-year career at West Pharmaceutical Services, where she held various senior roles in sales, strategy, and analytical operations.
DDL Recruits Jennifer Riter to Lead Analytical Testing Expansion
Jennifer Riter, a veteran with nearly three decades of pharmaceutical leadership, has joined DDL as Vice President of Analytical Testing. Based in Eden Prairie, Minnesota, she will oversee the laboratory’s GMP testing division, specifically focusing on drug-device combination products and specialized container closure integrity strategies.
At DDL, Riter will guide clients through the complexities of regulatory compliance and primary closure system strategies. Her mandate includes expanding the company’s GMP laboratory capabilities, with a primary focus on USP 1207 deterministic testing. General Manager John Koch noted that her technical background is intended to bolster the firm’s ability to support pharmaceutical and biotech innovation. DDL currently operates a 10,600-square-foot FDA-registered facility in Minnetonka, which handles stability studies and mechanical performance testing for products ranging from prefilled syringes to inhalers.
Comments (0)
No comments yet. Be the first!